Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by VA Loma Linda Health Care System.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Actelion
Information provided by:
VA Loma Linda Health Care System
ClinicalTrials.gov Identifier:
NCT00708565
First received: June 30, 2008
Last updated: July 1, 2008
Last verified: June 2008
  Purpose

The objective of this study is to determine if single dose administration of inhaled iloprost will reduce pulmonary artery pressure, reduce hypoxic pulmonary vasoconstriction and improve arterial oxygenation at rest and during exercise at high altitude.


Condition Intervention Phase
Hypoxic Pulmonary Vasoconstriction
Drug: iloprost
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude

Resource links provided by NLM:


Further study details as provided by VA Loma Linda Health Care System:

Primary Outcome Measures:
  • Exercise capacity, pulmonary artery systolic pressure, cardiac output, oxygen saturation [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Heart rate, tissue Doppler echocardiographic measurements [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: July 2008
Estimated Study Completion Date: October 2008
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: iloprost
    Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
    Other Name: Ventavis (brand name)
Detailed Description:

Three major pathways in addition to oxygen modulate pulmonary vascular tone: 1) nitric oxide, 2) endothelin, and 3) prostacyclin. Considerable animal data support the role of the prostacyclin pathway in modulating hypoxic pulmonary vasoconstriction. In humans, prostacyclin and its analogs are important therapeutic agents in the treatment of pulmonary arterial hypertension (PAH). Despite the animal data and human data in PAH there is very little information about the use of iloprost to relieve hypoxic pulmonary vasoconstriction in healthy humans. Inhaled iloprost is an ideal agent to study the prostacyclin pathway due to its short duration of action (30-90 min) and elimination half-life of only 20-30 min. Individuals already participating in the Nepal Medex 2008 trip will be invited to participate in this research. Participants will be healthy active females or males, between 18-80 years of age, without known pregnancy or liver disease, who have a readily measurable tricuspid regurgitant velocity by Doppler echocardiography. If possible, we will attempt to identify a cohort of HAPE susceptible patients. Participants will undergo evaluation both at sea level (baseline) and at high altitude. Baseline (low altitude) testing will be performed in Bangor, North Wales, UK, and will include evaluation of pulmonary artery systolic pressures, cardiac output, and oxygen saturation at rest and during submaximal exercise before and after inhalation of iloprost. This strategy will then be repeated at an altitude of approximately 5000 meters in the Dhaulagiri region of Nepal.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age: 18 - 80 years
  2. Healthy physically active males or females
  3. Have readily measurable tricuspid regurgitation (TR) peak systolic velocity by continuous wave Doppler ultrasound

Exclusion Criteria:

  1. Unable to measure TR velocity
  2. Known liver disease
  3. Pregnancy
  4. Nitrates, cyclosporin, glyburide or other medications that in the opinion of the investigators could place subjects at increased risk of complications
  5. Any other medical condition that in the opinion of the investigators would place the subject at high risk
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00708565

Locations
United States, California
Jerry L. Pettis VA Medical Center Recruiting
Loma Linda, California, United States, 92357
Contact: James D Anholm, MD    909-583-6098    James.Anholm@va.gov   
Sponsors and Collaborators
VA Loma Linda Health Care System
Actelion
Investigators
Principal Investigator: James D Anholm, MD Jerry L. Pettis VA Mecial Center
  More Information

No publications provided

Responsible Party: James D Anholm, MD, VA Loma Linda Healthcare System
ClinicalTrials.gov Identifier: NCT00708565     History of Changes
Other Study ID Numbers: 00769
Study First Received: June 30, 2008
Last Updated: July 1, 2008
Health Authority: United States: Federal Government

Keywords provided by VA Loma Linda Health Care System:
To study the effects of iloprost on hypoxic pulmonary vasoconstriction at high altitude

Additional relevant MeSH terms:
Iloprost
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasodilator Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on September 18, 2014